<DOC>
	<DOCNO>NCT01935843</DOCNO>
	<brief_summary>RATINALE : Placing tumor antigen chimeric receptor create laboratory patient autologous T cell may make body build immune response kill cancer cell . PURPOSE : This clinical trial study genetically engineer lymphocyte therapy treat patient HER-2 positive advance solid tumor , breast cancer , gastric cancer , hepatic carcinoma , endometrial cancer ovary cancer .</brief_summary>
	<brief_title>Treatment Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2 ( HER-2 ) Positive Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I.Determine safety feasibility chimeric antigen receptor T cell transduce anti-HER-2 vector ( refer CART-HER-2 cell ) . II.Determine duration vivo survival CART-HER-2 cell . RT-PCR ( reverse transcription polymerase chain reaction ) analysis whole blood use detect quantify survival CART-HER-2 TCR zeta : CD137 TCR ( T-cell receptor ) zeta cell time . SECONDARY OBJECTIVES : I.For patient detectable disease , measure anti-tumor response due CART-HER-2 cell infusion . II.Estimate relative traffic CART-HER-2 cell tumor bed . III.Determine cellular humoral host immunity develop murine anti-HER-2 , assess correlation loss detectable CART-HER-2 ( loss engraftment ) . IV.Determine relative subset CART-HER-2 T cell ( Tcm , Tem , Treg ) . OUTLINE : Patients assign 1 group accord order enrollment . Patients receive anti-HER-2-CAR ( couple CD137 CD3 zeta signal domain ) vector-transduced autologous T cell day 0,1 , 2 absence unacceptable toxicity . After completion study treatment , patient follow intensively 6 month , every 3 month 2 year , annually thereafter 13 year . Estimate relative traffic CART-HER-2 cell peripheral blood .</detailed_description>
	<criteria>Chemotherapy refractory HER2positive breast cancer , gastric cancer , nonsmall cell lung cancer , chemotherapy resistant relapse ovary cancer . Relapsed patient antiHER2 use antibody kinase inhibitor therapy . Patients must 18 year age old . Patients must ECOG ( Eastern Cooperative Oncology Group ) performance status 02 . Patients must evidence adequate bone marrow reserve , hepatic renal function evidence follow laboratory parameter : Absolute neutrophil count great 1500/mm3 . Platelet count great 100,000/mm3 . Hemoglobin great 10g/dl ( patient may receive transfusion meet parameter ) . Total bilirubin &lt; 1.5 time upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) . Seronegative HIV antibody . Seronegative active hepatitis B , seronegative hepatitis C antibody . Patients must willing practice birth control four month follow treatment.NOTE : woman childbearing age must evidence negative pregnancy test . Patients must willing sign inform consent . Patients life expectancy le 12 month exclude . Patients uncontrolled hypertension ( &gt; 160/95 ) , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated congestive heart failure ( &gt; New York Heart Association Class II ) , myocardial infarction within 6 month study exclude . Patients follow pulmonary function abnormality exclude : FEV ( forced expiratory volume ) , &lt; 30 % predict ; DLCO ( diffuse capacity lung carbon monoxide ) &lt; 30 % predict ( postbronchodilator ) ; Oxygen Saturation less 90 % room air . Patients severe liver kidney dysfunction consciousness disorder exclude . Pregnant and/or lactate woman exclude . Patients active infection , include HIV , exclude , due unknown effect vaccine lymphoid precursor . Patients type primary immunodeficiency exclude study . Patients require corticosteroid ( inhale ) exclude . Patients history T cell tumor exclude . Patients participate participated clinical trial late 30 day exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>CART-HER-2</keyword>
	<keyword>HER-2 positive</keyword>
	<keyword>Advanced</keyword>
	<keyword>Refactory</keyword>
	<keyword>Solid tumor</keyword>
</DOC>